SUMMARY. The renal microcirculation was assessed in non-clipped kidneys of 23 Munich-Wistar rats with two-kidney one-clip Goldblatt hypertension. Four weeks after placement of a renal arterial clip, mean systemic arterial pressure averaged 163 ± 5 mm Hg in hypertensive rats as compared to 108 ± 2 in sham-operated controls (n = 6 rats). Non-clipped kidneys in hypertensive rats were characterized by higher glomerular capillary hydraulic pressures, single nephron glomerular filtration rate, and afferent arteriolar resistance. The glomerular capillary ultrafiltration coefficient was significantly reduced in hypertensive rats. In 10 of these rats, intravenous infusion of the angiotensin antagonist, saralasin, or the converting enzyme inhibitor, SQ20881, led to significant reductions in systemic arterial pressure and in afferent and efferent arteriolar resistance, on average by 8 ± 3%, 15 ± 4%, 28 ± 5%, respectively. These changes were associated with significant increase in glomerular plasma flow, while ultrafiltration coefficient remained unaffected. In the presence of saralasin or SQ20881, infusion of a specific antagonist of the vascular action of arginine vasopressin led to significant systemic but not renal vasodilation. Thus, whereas systemic arterial pressure fell further, on average by 23 ± 2%, renal arteriolar resistance remained constant, resulting in marked reduction in glomerular capillary hydraulic pressures (by 18 ± 2%) and glomerular plasma flow rate (by 28 ± 10%). Because of these pronounced reductions in glomerular pressures and flows induced by vasopressin antagonist, single nephron glomerular filtration rate fell markedly in hypertensive rats (by 34 ± 6%) despite normalization of ultrafiltration coefficient. When hypertensive rats (n = 7) were treated with vasopressin antagonist alone, a modest fall in systemic arterial pressure was again observed in the absence of changes in renal arteriolar resistance. Due to this selective extrarenal vasodilatory action of vasopressin antagonist, glomerular capillary hydraulic pressure, plasma flow rate, and single nephron glomerular filtration rate again fell markedly. When these vasopressin antagonist pre-rreated hypertensive rats were given saralasin or SQ20881, marked reductions in renal arteriolar resistance were observed in association with a significant increase in glomerular plasma flow rate. These observations made during acute inhibition of angiotensin II and vasopressin indicate that both of these vasopressor hormones may play important roles in maintaining systemic hypertension in hypertensive rats. By virtue of its preferential constrictor effects on extrarenal rather than renal vasculature, vasopressin serves to maintain high glomerular pressures and flows in the non-clipped kidneys of Goldblatt hypertensive rats. (Circ Res 53: 592-602, 1983) TWO-KIDNEY one-clip Goldblatt hypertension (GH; see Glossary), an experimental form of renovascular hypertension, is characterized by elevations in plasma renin and All levels (Leenen et al., 1973) . Recent clearance and micropuncture studies have revealed that the circulatory dynamics of nonclipped kidneys of GH rats are substantially altered (Schwietzer and Gertz, 1979; Masaki et al., 1980; Schwietzer, 1980; Ploth et al., 1981; Huang et al., 1982a Huang et al., , 1982b Steiner et al., 1982) , in part, due to the renal vasoconstriction induced by All (Masaki et al., 1980; Schwietzer, 1980; Huang et al., 1982a Huang et al., , 1982b . On the other hand, based on the results obtained with use of an antibody against AVP, Mohring et al. (1978) have suggested that a vasoconstrictor action of AVP on systemic vasculature is also important for the maintenance of Goldblatt hypertension.
By employing specific antagonists directed against the vascular action of AVP (Manning et al., 1977; Lowbridge et al., 1978) , experimental evidence has recently been obtained to indicate that AVP plays an important role in the maintenance of systemic blood pressure under a variety of physiological and pathophysiological circumstances (Aisenbrey, et al., 1981; Andrews and Brenner, 1981; Schwartz and Reid, 1981; Zerbe et al., 1982) . Using one of these synthetic AVP antagonists, we undertook the pre- 
Methods
Studies were performed in adult male Munich-Wistar rats weighing 202-314 g. Four weeks prior to study, 34 rats were subjected to surgical placement of a 0.2-mm silver clip on the left renal artery under ether anesthesia. Seven other rats underwent sham surgery. Animals were allowed free access to a regular pellet diet and water, both before and after these procedures. Four weeks later, all rats were anesthetized with Inacrin (100 mg/kg, ip), and placed on a temperature-regulated micropuncture table. Immediately after the induction of anesthesia, the left femoral artery was catheterized with a PE-50 polyethylene tube, followed by a baseline collection of 70 //I of arterial blood. This arterial catheter was employed for subsequent periodic blood sampling and estimation of AP. AP was monitored with an electronic transducer (model P23Db, Statham Gould Inc.) . Polyethylene catheters were also inserted into the left and right jugular veins for infusion of inulin and pharmacological agents (or vehicle) and into the left femoral vein for infusion of isoncoric rat plasma. Intravenous infusions of homologous rat plasma (obtained at time of micropuncrure study by exsanguination of a littermate) and 10% inulin solution in 0.9% NaCl were started at rates of 7-10 ml/kg per hr, and 1.2 ml/hr, respectively. After tracheostomy, the right kidney was exposed by a subcostal incision and separated from the adrenal gland and the surrounding fat. The kidney was suspended on a Lucite holder, and its surface illuminated with a fiber-optic light source and bathed with isotonic NaCl heated to 35-37°C.
Since plasma volume of rats prepared for micropuncture is reduced by approximately 20%, relative to the conscious animal (khikawa et al., 1978) , the following protocol for maintaining the euvolemic state was employed. Soon after collection of the baseline arterial blood sample (see above), isoncoric rat plasma was infused for 60 minutes at the rate of 7-10 ml/kg per hr, followed by reduction in infusion rate to 1.5 ml/kg per hr for the remainder of each experiment in order to maintain the baseline hematocrit value obtained immediately after induction of anesthesia. In a previous study, this protocol was found to be successful in maintaining plasma volumes essentially equal to those prior to induction of anesthesia (khikawa et al., 1978) .
In all experiments, micropuncture measurements were carried out as follows: Exactly timed (1-to 2-minute) samples of tubule fluid were collected from surface proximal convolutions of two or three nephrons for determination of flow rate and inulin concentration. These measurements permit calculation of SNGFR. Coincident with these tubule fluid collections, two or three samples of femoral arterial blood were obtained in each period for determination of hematocrit and plasma concentrations of protein and inulin. Time-averaged hydraulic pressures were measured in surface glomerular capillaries (Pec) / proximal tubules (P T ), and surface efferent arteriole (P E ) with a continuous recording, servo-null micropipette transducer system (model 3, Instrumentation for Physiology and Medicine). Micropipettes with outer tip diameters of 2-3 nm and containing 2.0 M sodium chloride were used. Hydraulic output from the servo system was coupled electronically to a second channel of the Hewlett-Packard recorder by means of a pressure transducer.
Colloid osmotic pressure (TT) of plasma entering and leaving glomerular capillaries was estimated from values for protein concentrations (C) in femoral arterial (C A ) and surface efferent arteriolar (CE) plasma samples, by using the equation derived by Deen et al. (1973) . Values for CA, and thus TTA, for femoral arterial plasma are taken as representative of values for C and n for the afferent end of the glomerular capillary network. These estimates of preglomerular and postglomerular plasma protein concentration permit calculation of SNFF and K f , as well as resistances of single afferent (R A ) and efferent (R E ) arter- Group 1 (n = 10 rats) Group 2 (n = 7 rats) Group 3 (n = 6 rats) Group 4 (N = 6 rats) Group 5
(n = 7 rats) Group 6 (n = 4 rats) ioles and glomerular plasma flow rate (Q A ), by using the equations given elsewhere (Deen et al., 1973) .
Group 1 (GH): All-Inhibitor Followed by All Inhibitor and AVF Inhibitor Table 1 summarizes the protocol employed in the six groups of rats. In group 1(10 Goldblart hypertensive rats), the micropuncrure measurements and collections specified above were begun between 90 and 120 minutes after onset of surgical preparation, and completed in the subsequent 30-minute interval. At the end of this first study period, iv infusion of either saralasin (0.3 mg/kg per h; n = 4 rats) or SQ20881 (6 mg/kg per h; n = 6 rats) was started and continued throughout the duration of each experiment. After a 40-minute equilibration period, measurements of the various determinants of SNGFR were repeated. Immediately after completion of this second study period, each rat received a lOO-jzg iv bolus injection of [l-(/5-mercapto-/3,/?-cyclopentamethylene propionic acid) 4-valine-8-D-arginine] vasopressin, d(CH 2 ) 5 VDAVP (Lowbridge et al., 1978) , a structural analogue of arginine vasopressin. In a previous study (Andrews and Brenner, 1981) , this peptide was shown to block for at least 3 hours the 30-40 mm Hg rise in AP normally associated with a bolus injection of 50 mU AVP. Twenty minutes after injection of d(CH 2 ) 5 VDAVP, and while administration of saralasin or SQ20881 was continued, the above-described measurements and collections were again performed in the subsequent 30 minutes (third study period).
Group 2 (GH): AVP Inhibitor Followed by AVP Inhibitor and All Inhibitor
In group 2 (seven GH rats), we studied the effects of d(CH 2 ) 5 VDAVP alone, followed by the addition of saralasin or SQ20881 in the third study period. In these rats, the first study period was conducted in a fashion identical to that used in group 1. Subsequently, d(CH 2 ) 5 VDAVP was given as a bolus iv injection in a dose identical to that used in the third study period of group 1. Twenty minutes after this injection, measurements and collections of the quantities specified above were repeated during the next 30-minute interval. Immediately after this second study period, infusion of saralasin or SQ20881 was begun at the rate identical to that used for group 1. Following a 40-minute equilibrium period, pertinent measurements and collections were again started and completed in the subsequent 30-minute interval (third study period).
Group 3 (GH): Time Control
The time course of changes in renal microcirculatory and systemic dynamics was examined in group 3 (six GH rats) given no pharmacological agents. In this group, therefore, the time course and micropuncture procedures described above for groups 1 and 2 were duplicated, except that infusions of angiotensin inhibitor and AVP antagonists were omitted.
Group 4 (SHAM): All Inhibitor Followed by AH Inhibitor and AVP Inhibitor
In order to identify the specificity of the All and AVP antagonists employed in this study, we examined their effects on the systemic and renal cortical circulations in six sham-operated animals (group 4). In these rats, after completion of surgical preparation, the protocol described above for the group 1 three-period micropuncture study was duplicated.
Groups 5 and 6 (GH): Effect of AVP Inhibitor or Vehicle on Plasma Renin Concentration
Using two additional groups of GH rat (groups 5 and 6), we examined the effect of vasopressrn inhibition on the activity of the renin-angiotensin system. After surgical preparation identical to that described for micropuncture study, 500 y\ of blood were withdrawn from the femoral artery in each rat for the determination of PRC. Whole blood (500 n\), obtained on the morning of study from a littermate, was simultaneously infused via the femoral vein to replace the blood withdrawn. This donor littermate was maintained on 0.9% NaCl solution for drinking solution for a week until the time of exsanguinahon. After the initial blood sampling in GH rats, a bolus injection of either d(CH 2 ) 5 AVP, or [l-((3-mercapto-/3,/9-cyclopentamethylene propionic acid)] arginine vasopressin, another synthetic AVP analogue possessing a specific antagonistic effect against the vascular action of AVP similar to d(CH 2 ) 5 VDAVP (Kruszynski et al., 1980 ) (100 Mg; group 5; n = 7 rats), or sham solution (group 6; n = 4 rats) was given iv. Twenty minutes later, 500 )A of blood were again collected from the femoral artery in these GH rats for the second determination of PRC. During this collection, whole blood was replaced simultaneously, as in the first collection.
Analytic
The volume of fluid collected from individual proximal tubules was estimated from the length of the fluid column in a constant-bore capillary tube of known internal diameter. The concentration of inulin in tubule fluid was measured, usually in duplicate, by the microfluorescence method of Vurek and Pegram (1966) . Inulin concentration in plasma was determined by the macroanthrone method of Fuhr et al. (1955) . Protein concentrations in efferent arteriolar and femoral arterial blood plasmas were determined, usually in duplicate, by the fluorometric method of Viets et al. (1978) . PRC was determined as the amount of Al generated in 1 hour at 37°C in a reaction mixture (total volume of 350 ^1) containing the sample (80 ^1 of plasma), anephric dog plasma (200 ^1), dimercaptopropanol, and 8-hydroxyquinolone (0.34 ITIM) in 0.1 M Tris-HC1, pH 7.4, according to the modified assay of Haber et al. (1969) .
Statistical analyses were performed by the paired and unpaired f-test, where appropriate. Statistical significance is defined as P < 0.05.
Results

Functions during Basal Euvolemic Conditions
Mean values for body weight, AP, and a number of pertinent measures of whole kidney and single nephron function in non-clipped (right) kidneys of 23 Goldblatt hypertensive rats (groups 1, 2, and 3) are summarized in Table 2 . Also given are mean values for right kidneys of seven sham-operated rats (group 4). In the 23 GH rats, marked hypertension was evident, with AP averaging 163 ± 5 mm Hg vs. 108 ± 2 in SHAM animals. These two groups were similar with respect to body weight. Kidney weight was slightly but significantly higher in GH rats than in SHAM animals, on average by 20%. Although not shown in Table 2 , this hypertrophy of the nonclipped kidney in GH rats was accompanied by hyporrophy of the clipped kidney within the same animals, as indicated by the fact that the average weight of the latter (0.86 ± 0.07 g) was ~15% lower than that of SHAM kidneys.
A higher intravascular pressure was also detected at the level of glomerular capillary network in the non-clipped kidneys of Goldblatt hypertensive rats. Pec averaged 64 ± 2 mm Hg, a level 16 mm Hg higher than that obtained in SHAM control kidneys. Since P T was unaffected in GH, AP was also markedly elevated, on average to 15 mm Hg above SHAM control levels. Elevated intravascular hydraulic pressure was also recorded in P E . These two groups did not differ in systemic plasma protein concentration, CA, or oncotic pressure, TT A . In contrast, efferent arteriolar plasma protein concentration, C E , and oncotic pressure, TT E , averaged 8.8 ± 0.2 g/dl and 37 ± 1 mm Hg, respectively, in hypertensive rats, values significantly higher than those in SHAM animals. Thus, SNFF values were also significantly higher in GH than SHAM control rats (0.33 ± 0.01 vs. 0.28 ± 0.02, P < 0.05).
In association with this high SNFF, values for SNGFR were found to be significantly elevated in GH, averaging 53.7 ± 2.2 vs. 40.6 ± 3.7 nl/min in n, . ±0.4
NS NS SHAM (P < 0.01). However, the mean value for glomerular plasma flow rate, Q A , for GH was not significantly higher than in SHAM. As with Q A , we observed mild elevations in RA, whereas no significant change was observed in R E in GH. In contrast to SHAM animals, values for ir E /AP in GH were less than unity (on average, 0.78 ± 0.03), denoting failure to achieve filtration pressure equilibrium by the efferent-most portion of the glomerular capillary network. Unique values for K f thus calculated averaged 0.051 ± 0.007 nl/(sec X mm Hg) in GH, a value significantly lower than that obtained in SHAM controls (0.088 ± 0.016, P < 0.025) or those for normal euvolemic Munich-Wistar rats previously reported from this laboratory (Ichikawa et al., 1978) .
Group 1 (GH): Effects of All Inhibitor and All Inhibitor + AVP Inhibitor
Since results obtained with infusion of saralasin or SQ20881 were indistinguishable, those data are pooled in all calculations in groups 1, 2, and 4. Infusion of saralasin (n = 4) or SQ20881 (« = 6) alone in group 1 GH_rats resulted in a mild but 
NS NS
Values are expressed as means ±1SE; NS: P > 0.05. * One, | four, H two, or J three minimum K f values are included in the calculation. § Changes from first to second study period; | changes from second to third study period. significant decrease in AP from 161 ± 9 mm Hg to 147 ± 8 (Table 3) . P GC also fell significantly, on average, from 62 ± 3 mm Hg to 55 ± 1, whereas P E was essentially unaffected, as shown. Since P T remained at the pre-infusion level, AP decreased from an initial mean value o f 4 7 ± 3 t o 4 1 ± l mm Hg with SQ20881 or saralasin. C A and, thus 7r A remained unchanged between the first and second study periods, whereas values for C E and, thus,, ir E showed a significant fall (from 8.9 ± 0.2 to 8.0 ± 0.2 g/dl and from 38 ± 1 to 32 ± 1 mm Hg, P < 0.005 for both).
As also shown in Table 3 , Q A tended to increase slightly with saralasin or SQ20881 infusion (from 161 ± 13 to 177 ± 16 nl/min, P < 0.05), while SNGFR fell slightly (from 55.2 ± 3.8 to 51.8 ± 3.0 nl/min)*. Thus, SNFF fell significantly during infu- sion of saralasin or SQ20881, on average from 0.35 ± 0.02 to 0.30 ± 0.01 (P < 0.005). R A and R E both tended to fall slightly, but the change was significant only for R E , as shown in Table 3 . Filtration pressure disequilibrium persisted during angiotensin blockade, as indicated by the mean value of ir E / AP, which remained significantly below unity (0.78 ± 0.03). Unique values for Kf thus calculated averaged 0.059 ± 0.006 nl/(sec X mm Hg), a value not different from that obtained before saralasin or SQ20881 infusion.
During continued infusion of angiotensin blockade, the addition of d(CH 2 ) 5 VDAVP injhe third study period served to further decrease AP to levels (111 ± 8 mm Hg, P < 0.001) similar to those measured in SHAM control animals ( Table 3 ). P G c and P E also fell significantly, on average by 12 and 2 mm Hg, respectively. Since P T changed only slightly, AP fell to the level (31 + 1 mm Hg) measured in SHAM control kidneys. Whereas mean values for C A and W A again remained essentially constant, those for C E and ir E fell significantly. Thus, although Q A fell significantly with d(CH 2 ) 5 VDAVP infusion, from 177 ± 16 to 122 ± 9 nl/min (P < 0.001), a proportionately greater reduction was seen in SNGFR (from 51.8 ± 3.0 to 30.2 ± 3.2 nl/min, P < 0.001). Of note is the fact that values for R A and R E were both essentially constant during the third study period, indicating that the fall in Q A seen in non-clipped kidneys of these hypertensive rats must have been evoked primarily by alterations in extrarenal circulatory dynamics. During d(CH 2 ) 5 VDAVP, filtration pressure disequilibrium, as defined by TT E /AP 0.95, was achieved in six of these 10 GH rats. Mean values of the unique Kf values calculated in these six rats, as well as of minimum K f values in the remainders, averaged 0.092 ± 0.014 nl/(sec X mm Hg), a value significantly higher than those obtained during the initial control period or during All inhibitor infusion alone in the same kidneys, but essentially identical to those found in SHAM control animals.
Group 2 (GH): Effects of AVP Inhibitor and AVP Inhibitor + All Inhibitor
Administration of d(CH 2 ) 5 VDAVP in the second study period in group 2 GH rats led to a modest and significant fall in AP, on average from 167 ± 10.to 141 ±_7 mm Hg (P < 0.005) (Table 3) . Likewise, P GC and AP fell significantly from 63 ± 4 to 52 ± 2 mm Hg (P < 0.025) and from 51 ± 4 to 40 ± 2 mm Hg (P < 0.01), respectively, while P T remained unchanged. Values for C A and TT A were essentially constant during the initial and second study periods. In contrast to the pattern seen with the infusion of saralasin or SQ20881 alone in group 1, administration of d(CH 2 ) 5 VDAVP alone failed to alter values for C E , TT E , and, hence, SNFF. Also, in contrast to results found in group 1 rats during All blockade alone (but in a manner similar to that seen with in the third study period in group 1), infusion of Circulation Research/Vo/. 53, No. 5, November 1983 d(CH 2 ) 5 VDAVP alone in group 2 rats led to a marked reduction in Q A , from 174 ± 25 to 116 ± 23 nl/min (P <0.01). This fall in Q A was accompanied by small but not statistically significant increases in R A and R E . In conjunction with the constancy in SNFF, SNGFR also fell markedly, with d(CH 2 ) 5 VDAVP alone, from 52.8 ± 3.2 to 34.9 ± 3.9 nl/min (P < 0.001). As with All blockade alone, d(CH 2 ) 5 VDAVP alone failed to alter values for K f so that filtration pressure disequilibrium persisted, as indicated by TT E /AP values, remaining significantly less than unity during the second study period (Table 3).
In these seven d(CH 2 ) 5 VDAVP-treated group 2 GH rats, saralasin (n = 3) or SQ20881 (n = 4) was given in the third period in a dose identical to that used in group 1 rats. As in the third period of group 1, the combined use of d(CH 2 ) 5 VDAVP and saralasin or SQ20881 in group 2 rats led to further reduction in AP, from J141 ± 7_to_120 ± 8 mm Hg (P < 0.005). Likewise, P G c and AP fell significantly to levels (47 + 2 and 35 ± 1 mm Hg) which were comparable to those measured in SHAM controls. P T was again unaffected throughout, as were values for C A and ir A . AS with saralasin or SQ20881 infusion alone, All blockade in rats pretreated with d(CH 2 ) 5 VDAVP led to significant falls in C E , w E , and SNFF (Table 3) . Nevertheless, since Q A again increased significantly with saralasin or SQ20881 infusion (from 116 ± 23 to 148 ± 22 nl/min), SNGFR did not fall despite the reduction in SNFF. This rise in Q A was associated with significant reductions in both R A and R E , on average, from 3.6 ± 0.6 x l0 10 dynes sec/cm 5 to 2.2 ± 0.4 (P < 0.005) and from 1.6 ± 0.3 to 1.1 ± 0.2 (P < 0.025), respectively. As seen earlier in group 1 hypertensive rats, the combined use of d(CH 2 ) 5 VDAVP and saralasin or SQ20881 led to a significant rise in K f above initial baseline level, whereas K f values were unaffected by the presence of either inhibitor alone.
Group 3 (GH): Time Control
In the absence of pharmacological manipulation, the various indices of single nephron and glomerular microcirculatory function measured in a separate group of GH rats remained statistically unchanged over the time course of group 1 and 2 studies (Table  3 ). The only exceptions were small but uniform reductions in C A and TT A during the transition from the second to the third study period, and this tendency was seen in groups 1 and 2 as well.
Group 4 (SHAM): Effects of All Inhibitor and AVP Inhibitor
As shown in the bottom of Table 3 , saralasin (« = 4) or SQ20881 (n= 6) infusion in group 4 SHAM rats failed to alter AP, P GC , AP, SNGFR, Q A , C E , * E , SNFF, R A , R E , ir E /AP, or K f significantly. Likewise, addition of d(CH 2 ) 5 VDAVP to these saralasin or SQ20881 pretreated SHAM rats also failed to alter these quantites. Thus, in the doses employed in the present study, these various pharmacological agents were without effect on the systemic or renal vasculature of non-hypertensive rats.
Groups 5 and 6 (GH): Effect of AVP Inhibitor on Plasma Renin Concentration
PRC was measured in seven GH rats (group 5) before and after d(CH 2 ) 5 AVP injection, and the results were compared with those following vehicle injection alone (group 6). As shown in Table 4 , whereas PRC remained unchanged in group 6 rats given vehicle alone, PRC uniformly increased after d(CH 2 ) 5 VDAVP injection in group 5 rats, by 30% above initial values (P < 0.05).
Discussion
In the two-kidney Goldblatt hypertensive rat, increased renin and angiotensin II production has been incriminated in the initiation and maintenance of systemic hypertension (Brunner et al., 1971; Bengis and Coleman, 1979; Carretero et al., 1971; Freeman et al., 1979; Huang et al., 1982a Huang et al., , 1982b . To evaluate the role of the renin-angiotensin system in the observed alteration in the renal microcirculation, the effects of the angiotensin II antagonist, saralasin, or SQ20881, an angiotensin I-converting enzyme inhibitor, were studied in non-clipped kidneys of Goldblatt hypertensive rats. These inhibitors led to modest reductions in both systemic arterial and glomerular capillary hydraulic pressure, on average by 14 and 7 mm Hg, respectively. Moreover, this pharmacological blockade of All action led to uniform reductions in both afferent and efferent arteriolar resistances, with proportionately greater decreases in the latter. This arteriolar vasodilation was sufficient to cause a slight but significantjncrease in Q A in the face of a small decline in AP (shaded bars given on the left in Fig. 1 ). All inhibitor-induced arteriolar vasodilations and increases in glomerular plasma flow rate have been found to occur in other conditions characterized by high endogenous levels of All (Steiner et al., 1979; Ichikawa and Brenner, 1980; Schor et al., 1981a Schor et al., , 1981b . In many, although not all (Steiner et al., 1979; Tucker and Blantz, 1983) of these studies, values for Kf, which were low prior to AH inhibition, were often normalized by infusion of an All inhibitor (Ichikawa and Brenner, 1980; Schor et al., 1981a Schor et al., , 1981b Pelayo and Blantz, 1982) . Also, administrtion of exogenous All has been shown to cause a marked reduction in K f (Blantz et al., 1976; Baylis and Brenner, 1978; Ichikawa et al., 1979) . In contrast to these previous observations, values for Kf remained low during All inhibition in the present study, implying the presence of other factor(s) contributing to the low level of K f in nonclipped kidneys of Goldblatt hypertensive animals.
599
In view of the recent evidence obtained by Mohring et al. (1978) and Woods and Johnston (1982) indicating that the circulating level of AVP is markedly elevated in two-kidney Goldblatt hypertension, an effort was made in the present study to determine the functional role of vasopressin in the renal cortical microcirculation in this model. For this purpose, we infused d(CH 2 )sVDAVP, an arginine vasopressin analogue capable of specifically antagonizing the pressor effects of AVP (Lowbridge et al., 1978; Crofton et al., 1979; Aisenbrey et al., 1981; Andrews and Brenner, 1981) . In Goldblatt hypertensive rats pretreated with saralasin or SQ20881 (group 1), infusion of this specific AVP antagonist led to further declines in AP and P G C-Clearly, normalization of AP and P e c required inhibition of both All and AVP, and these observations can be taken as evidence of activation of both these pressor systems in Goldblatt hypertensive rats.
Unlike All inhibition alone, simultaneous AVP inhibition led to a marked reduction in glomerular plasma flow rate. Due to the combined reductions in both P GC and Q A , SNGFR also fell markedly. The observed profound fall in Q A in the face of systemic arterial vasodilation (i.e., marked fall in AP) is suggestive of a vasodilatory action of d(CH 2 )sVDAVP which is more pronounced in the extrarenal than the intrarenal vascularures (the shaded bars given on the right in Fig. 1 ). Indeed, in GH rats given an angiotensin inhibitor (group 1), addition of the AVP inhibitor failed to alter values for R A and R E , in contrast to the pattern seen with All inhibition alone. Therefore, AVP, in this model, appears to maintain high renal perfusion and filtration by raising the systemic but not the renal vascular tone. In keeping with these in vivo observations, Schmid et al. (1974) found that the extrarenal vasculature, such as the mesenteric artery, was more sensitive to the constrictor action of exogenously administered AVP than was the renal vasculature, whereas the opposite relationship existed for the responsiveness to AIL In our recent study conducted in acutely water-deprived rats, such a preferential extrarenal vasoconstrictor action of AVP was demonstrated. Specifically, a substantial fall in whole kidney blood flow : cardiac output ratio after a vascular AVP antagonist was observed (Ichikawa et al., 1983) .
Of additional interest, K f values which were unaffected during All inhibition alone, increased significantly in the presence of both All and AVP inhibitors (group l)f. Since administration of SQ20881 or saralasin also raises Kf in d(CH 2 ) 5 VDAVP-pretreated animals (group 2), these findings indicate that both All and AVP are contributing to the low level of K f , seen in non-clipped kidneys of Goldblatt hypertensive rats. In view of the previous observations that both All and AVP are capable of reducing K f in normal rats (Blantz et al., 1976; Ichikawa and Brenner, 1977; Baylis and Brenner, 1978; Ichikawa et al., 1979; Schor et al., 1981b) , the present findings with d(CH 2 ) 5 VDAVP and saralasin or SQ20881 can be taken as evidence for an intraglomerular action of All and AVP in non-clipped kidneys of rats with Goldblatt hypertension.
Many of the patterns seen with the AVP inhibitor administration in SQ20881 or saralasin-pretreated animals (group 1) were duplicated when the same AVP inhibitor was given alone (group 2). Thus, with Fig. 1 ). However, some important differences were noted in the intrarenal effect of d(CH 2 ) 5 VDAVP in the presence vs. absence of concurrent All inhibition. As discussed earlier, the AVP inhibitor given alone failed to raise values for K f . Moreover, in contrast to the All inhibitor-induced reduction in SNFF seen in All inhibitor-pretreated rats (group 1), values for SNFF remained relatively high during AVP inhibition alone (group 2). Furthermore, values for arteriolar resistances were seen to increase mildly, although not significantly, in response to AVP inhibitor alone (open bar, bottom left, Fig. 1 ). These patterns during d(CH 2 ) 5 VDAVP infusion, namely, low Kf, high arteriolar resistances, and increased filtration fraction, are reminiscent of the intrarenal action of AIL Our measurements of PRC in an additional group of GH rats further support this possibility. In these GH rats, infusion of d(CH 2 ) 5 VDAVP, another potent antagonist of the pressor effects of AVP, raised PRC significantly above the preinfusion level. It is then conceivable that, because of a compensatory augmentation in circulating All levels, AP remained relatively higher during AVP inhibition in our study. The importance of such an angiotensin-vasopressin interaction for the maintenance of AP has been demonstrated previously in rats deprived of water for 24 hours (Andrews and Brenner, 1981) . In that study, a profound hypotensive effect of AVP inhibition was seen only when All action was concomitantly inhibited by administrtion of an All antagonist or bilateral nephrectomy. Of note are the recent findings by Woods and Johnston (1982) . In their study in the Long-Evans strain of rats, hypertension and elevated plasma AVP levels occurred after clipping of one renal artery. Similar hypertension was also observed following unilateral renal arterial clipping in Brattleboro rats with hypothalamic diabetes insipidus. In the latter, a group of other vasopressor mechanisms, such as All and adrenergic systems, may come into play to account for the hypertension. Of interest, Rabito et al. (1981) have recently reported that an AVP antagonist, identical to that used in the present study, failed to reduce systemic arterial pressure or to raise PRC in two-kidney Goldblatt hypertensive rats which were studied when "malignant hypertension" was established. Since their hypertensive rats had 10-fold higher average plasma renin levels than were measured in the present study, it seems likely that the relative contributions of AVP and All in the maintenance of Goldblatt hypertension vary during the course of this disorder.
In a recent study using magnetic flow probe, Ploth et al. (1981) found that non-clipped kidneys of twokidney Goldblatt hypertension are characterized by impaired autoregulatory capacity of the renal vasculature, i.e., whole kidney blood flow decreased in direct proportion to the step-wise reduction in renal perfusion pressure by aortic snare. In keeping with these observations made at the whole kidney level, we found marked reductions in Q A and SNGFR during the step-wise fall in systemic arterial pressure induced by All and AVP inhibitors. Moreover, PGC fell markedly with the fall in AP. Uis clear from our findings that these falls in Q A , P GC , and SNGFR were due to an absence of afferent arteriolar vasodilation in the face of reduction in renal perfusion pressure. Given this impaired autoregulatory capacity in non-clipped kidneys, AVP-induced extrarenal vasoconstriction and systemic hypertension become even more crucial for the maintenance of glomerular perfusion and filtration in the kidneys. Were this AVP vasopressor action not operating, it seems likely that the renal perfusion pressure would not be kept at a high level, so that glomerular perfusion and filtration would be expected to be attenuated markedly.
Finally, it should be recognized that our observations of acute inhibition of vasopressor hormones emphasize the important contribution of these substances in the altered renal microcirculatory dynamics in this form of hypertension, during the period we studied. However, our study does not ascertain their roles in the development of hypertension or their function in chronic malignant hypertension.
